CapsoVision enters the second half of 2026 as a single-product capsule endoscopy company whose investment narrative has fundamentally reshaped around a freshly authorized equity issuance mechanism rather than its modest current revenue trajectory. The commercial story is small-bowel. The strategic story is gastrointestinal colon imaging, where a pivotal study has just completed enrollment in preparation for a regulatory submission. The financial story is a textbook post-IPO liquidity reset, and these threads explain why management concluded substantial doubt existed about the Company's ability to continue as a going concern within twelve months, even while establishing a theoretical capital runway several times larger than the prior balance-sheet ceiling.
The commercial engine remains the CapsoCam Plus capsule. Unit shipments grew 13% in the most recent quarter, partially offset by a 3% drop in average selling price as competitive intensity in the small-bowel capsule category ticked higher. International mix expanded to 25% of revenue in the latest quarter from 23% a year earlier, anchored by shipments to France, Germany, and Saudi Arabia. Margins slipped alongside price; gross margin fell into the low fifties from the mid-fifties in the prior-year period, with U.S. tariff policy on Asian-sourced components identified as a discrete headwind. Operating expenses outran revenue at every line item, lifting the operating loss meaningfully. The franchise is growing modestly and burning cash faster than it is growing top line, which makes the financing thread above the operating one in importance.
The strategic story is the CapsoCam Colon capsule. The product is a panoramic imaging capsule designed for large-bowel examination, integrating a 3D sensor that enables AI-assisted polyp detection and polyp-size measurement. A first-generation regulatory submission was withdrawn in late 2025 after the FDA raised questions on panoramic image processing methodology and pivotal study design. The Company pivoted to a second-generation device featuring a new CMOS image sensor developed under an agreement with Canon Inc., supported by a multi-site pivotal study now fully enrolled. A new regulatory submission is targeted for Q4 2026. Approval would address a meaningfully larger patient population than the small-bowel indication, and management expects Colon units to command higher selling prices than CapsoCam Plus because of additional optical and AI features. The clinical and regulatory timeline is the dominant forward variable in the story.
The financial story is the most consequential for the equity in the near term. Following the July 2025 IPO, management executed a private placement that totaled $14M of gross proceeds. Cash on the balance sheet at the most recent quarter-end stood at $9.1M, against operating cash burn in the mid-teens of millions for the half-year. Five days after the period-end, the Company entered a Controlled Equity Offering sales agreement with Cantor Fitzgerald authorizing the issuance of up to $100M of common stock from time to time through an at-the-market mechanism. That single transaction converts the going-concern overhang from a binary twelve-month countdown into a manageable, discretionary dilution path. The investment debate is no longer whether the franchise runs out of cash before reaching a Colon approval. The debate is now how aggressively the shelf is drawn, on what timeline, and against what clinical milestones. Investors should anchor analysis on four sequential binary events: the Q4 2026 Colon filing, the small-bowel AI clearance expected by quarter-end, the Colon clearance itself, and the rate at which Cantor is tapped.